Diffuse large B-cell lymphoma recurrent

9 trials 2 recruiting MedDRA PT
9 Registered trials
2 Recruiting
8 Unique sponsors
30 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
A Gastroenterology (ATC A) 2
H Endocrinology (ATC H) 3
J Anti-infectives (ATC J) 2
L Oncology (ATC L) 6
N Neurology/Psychiatry (ATC N) 3
R Respiratory (ATC R) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Antimetabolite 3 substances
Corticosteroid 2 substances
CAR-T cell therapy 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Alkylating agent 1 substance
Antiviral 1 substance
Analgesic / antipyretic 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody 1 substance
BTK inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Platinum compound 1 substance
IMiD 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (rat) 1 substance
Phase II: 5 Phase I/II: 2 Phase I: 2

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase II

5 trials
  • Allogene Therapeutics Inc. Commercial
    ALLO-501A; ALLO-647; CYCLOPHOSPHAMIDE; FAMOTIDINE; FLUDARABINE PHOSPHATE; HYDROCORTISONE; LETERMOVIR; LORATADINE; PARACETAMOL; PROMETHAZINE HYDROCHLORIDE; TOCILIZUMAB
    2022-501927-25-00 2 countries 2023 n=35
    Ended
  • Allogene Therapeutics Inc. Commercial
    ALLO-501A; ALLO-647; CYCLOPHOSPHAMIDE; FAMOTIDINE; FLUDARABINE PHOSPHATE; FLUDARABINE PHOSPHATE PH. EUR.; HYDROCORTISONE; LETERMOVIR; LORATADINE; PARACETAMOL; PROMETHAZINE HYDROCHLORIDE; TOCILIZUMAB
    2023-503830-27-00 3 countries 2023 n=35
    Ended
  • AstraZeneca AB Commercial
    HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2023-505789-27-00 6 countries 2025 n=82
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial
    AXICABTAGENE CILOLEUCEL; GLOFITAMAB; LISOCABTAGENE MARALEUCEL; OBINUTUZUMAB
    2025-523806-34-00 1 country n=20 Orphan
    Pending
  • Instytut Hematologii I Transfuzjologii Academic
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CISPLATIN; CYTARABINE; DEXAMETHASONE; LENALIDOMIDE; POLATUZUMAB VEDOTIN; RITUXIMAB; TAFASITAMAB
    2024-518275-64-00 1 country n=340 Orphan
    Pending

Phase I/II

2 trials
  • BeOne Medicines AG Commercial
    BGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
    2024-516234-35-00 3 countries 2025 n=99 Orphan
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    MOSUNETUZUMAB; POLATUZUMAB VEDOTIN; TOCILIZUMAB
    2023-507498-16-00 2 countries 2019 n=39 Orphan
    Ended

Phase I

2 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-509969-20-00 2 countries 2017 n=127
    Ended
  • Emercell SAS Commercial
    IMP not specified
    2024-511843-24-00 1 country n=10
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Allogene Therapeutics Inc. Commercial 2 Phase II 0
Celgene Corp. Commercial 1 Phase I 0
Emercell SAS Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial 1 Phase II 0
BeOne Medicines AG Commercial 1 Phase I/II 1
F. Hoffmann-La Roche AG Commercial 1 Phase I/II 0
Instytut Hematologii I Transfuzjologii Academic 1 Phase II 0
New trials by year
2019
1
2023
2
2025
2
← All indication landscapes